Blanket Purchase Agreement 36F79718D0403-36E79720A0012
Award Date
5/22/20
Last Date to Order
5/21/25
Federal Agency
National Acquisition Center
Awardee
Daiichi Sankyo, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) awarded Daiichi Sankyo, Inc., a pharmaceutical manufacturer, a Federal Supply Schedule (FSS) contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB). The contract, valued at $411,900,000, has an ultimate completion date of October 1, 2025. Daiichi Sankyo provides specialty pharmaceutical products, primarily the drug pexidartinib (marketed as TURALIO), to VA healthcare facilities nationwide through a single-award Blanket Purchase Agreement...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the Department of Veterans Affairs (VA) to Daiichi Sankyo, Inc., a pharmaceutical manufacturer. The single-award BPA, valued at $80,206.95, provides a mechanism for VA healthcare facilities nationwide to efficiently procure the specialty drug pexidartinib (marketed as TURALIO) in various dosage forms. Pexidartinib is used to treat tenosynovial giant cell tumor, a rare disease, in eligible veteran patients....
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The single-award BPA, valued at over $13 million, is for the supply of the oncology medication ICLUSIG (ponatinib) to various VA Medical Centers and Veterans Integrated Service Networks (VISNs)...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025.
The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...
Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, holds a $360,141,120 multiple-award Federal Supply Schedule contract (36F79718D0586) with the U.S. Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs (FSS-61-IB). As a prime contractor, Takeda leverages this IDV to efficiently supply critical oncology medications like ICLUSIG (ponatinib) and NINLARO (ixazomib) to VA medical facilities and Veterans...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract and a single award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide pharmaceuticals and drug products.
The FSS contract, valued up to $78 million through July 2025, and the BPA, valued up to $11.75 million from October 2021 to September 2025, allow the VA to procure pharmaceuticals such as TEGSEDI, used to treat...
Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, is the prime contractor on this General Services Administration (GSA) Indefinite Delivery Vehicle (IDV) contract to provide a range of specialty pharmaceutical products to various U.S. government agencies, including the Department of Veterans Affairs (VA), Department of Justice Bureau of Prisons, and Department of Defense.
The contract, which has a ceiling value of...
The U.S. Department of Veterans Affairs (VA) has awarded Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, two significant Indefinite Delivery Vehicles (IDVs) to facilitate the procurement of pharmaceutical products. The first is a $15 million Blanket Purchase Agreement (BPA) specifically for the delivery of Jynarque (tolvaptan), a medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The second is a $396 million Federal Supply...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) contract to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company, to provide the medication TARPEYO. This BPA, valued at $1,750,000 and running through April 2026, designates Calliditas Therapeutics US Inc. as the sole approved supplier of TARPEYO to VA medical facilities nationwide.
TARPEYO is an innovative treatment for uncontrolled protein in the urine due to primary...